What happened
AstraZeneca PLC (NYSE: AZN) reported nine-month total revenue of $46.88 billion, up 7% at constant exchange rates, and kept its full-year guidance.
Core EPS rose 14% to $8.00, and Core operating profit grew at the same rate. Third-quarter total revenue of $16.21 billion also grew 7%.
The drugmaker said it completed a $2.0 billion equity investment in Summit Therapeutics Inc. on Oct. 5, paid in full at closing. The stake gives AstraZeneca rights equal to about 12.0% of Summit's common stock, or about 10.6% on a fully diluted basis.
The two companies will also test sonesitatug vedotin with Summit's PD-1/VEGF bispecific antibody ivonescimab.
For the full year, AstraZeneca expects total revenue to rise by a mid-to-high single-digit percentage and Core EPS by a low double-digit percentage, both at constant exchange rates.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Total Revenue, nine months (change at constant exchange rates) | $46.88 billion | +7% | SEC Form 6-K |
| Core EPS, nine months | $8.00 | +14% | SEC Form 6-K |
| Reported EPS, third quarter | $2.02 | +23% | SEC Form 6-K |
| Total Revenue, third quarter | $16.21 billion | +7% | SEC Form 6-K |
| Enhertu combined sales, nine months | $4.68 billion | from $3.58 billion, +30.8% | Calculated from SEC Form 6-K |
| Equity investment in Summit Therapeutics Inc. | $2.0 billion | SEC Form 6-K |
Read more: AstraZeneca (AZN) company research
Why it matters
Growth in three therapy areas is outrunning the drugs losing exclusivity. At constant exchange rates, nine-month Oncology revenue rose 16%, respiratory and immunology 10% and rare disease 11%. Farxiga product revenue fell 15% and Brilinta 62%.
By OptimistFi's calculation, Enhertu combined sales rose 30.8% in the first nine months, to $4.68 billion from $3.58 billion a year earlier. The figure adds sales recorded by Daiichi Sankyo and AstraZeneca.
The results fit OptimistFi's view that AstraZeneca works when clinical differentiation turns into high-margin global revenue faster than patent, payer and pipeline risks erode it. Third-quarter gross margin was 82%, up 1 percentage point at constant exchange rates.
The filing also shows setbacks. Volrustomig was discontinued for futility in a first-line lung cancer trial. An Ultomiris trial in delayed graft function was discontinued for lack of efficacy. Etcamah missed its main goal in the SERENA-4 breast cancer trial.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
AstraZeneca plans to publish fourth-quarter and full-year 2026 results on Feb. 9, 2027. Results inside the guided ranges for revenue and Core EPS would support the case. A shortfall would weaken it.
Its Reshaping for Sustainable Growth programme is expected to cost up to $2.0 billion in one-time restructuring costs and deliver $1.5 billion in annualised pre-tax run-rate benefits. AstraZeneca expects the work to be essentially complete by the end of 2029.
More from OptimistFi
From OptimistFi Perps
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
Sources
- AstraZeneca PLC Form 6-K, 3rd Quarter Results (9M and Q3 2026) — Results announcement dated Oct. 30, 2026, covering revenue, Core EPS, guidance, the Summit Therapeutics investment and pipeline milestones.
Explore OptimistFi research on AstraZeneca PLC: https://optimistfi.com/stocks/AZN
Browse AstraZeneca PLC company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the AstraZeneca PLC company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
